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Steven De Vleeschouwer6, Stefaan Van Gool6, Franc¸oise Poirier8, Vincent Castronovo5, Robert Kiss1,9
and Olivier Feron7
Aggressiveness of advanced melanomas relates in part to their marked propensity to develop neoangiogenesis
and metastases. Among its numerous pro-cancer roles, galectin (gal)-1 expressed and/or secreted by both
cancer and endothelial cells stimulates proliferation and angiogenesis. This study first shows that gal-1 is more
highly expressed at both mRNA and protein levels than its congeners in melanomas and particularly in
advanced lesions. The roles of gal-1 were further investigated in vivo in the highly proliferating and vascularized
pseudometastatic B16F10 mouse melanoma model using stable knockdown B16F10 cells and wild-type versus
gal-1 knockout mice, and then in vitro in B16F10 tumoral and lung microvascular cells. Gal-1 depletion in the
B16F10 tumor cells but not in the tumor-bearing mice significantly increased melanoma-bearing mice survival.
Tumor-derived gal-1 thus seems to have more critical roles than the host-derived one. In fact, gal-1 displays
distinct effects on the H-Ras-dependent p53/p21 pathways: in primary lung microvessel endothelial cells, gal-1
seems to be involved in the maintenance of senescent status through the induction of both p53 and p21 while it
stimulates B16F10 cancer cell proliferation through a p53/p21 decrease. Altogether, these data point to gal-1 as a
potential target to combat melanomas.
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INTRODUCTION
As soon as melanomas have metastasized, they represent one
of the most devastating cancer types, with o45% survival 1
year after diagnosis (Balch et al., 2004). This poor prognosis
relates mainly (i) to the marked resistance of melanoma cells
to pro-apoptotic stimuli and thus to conventional chemother-
apy (La Porta, 2009), with clinical response rates that do not
exceed 15–20% (Mouawad et al., 2010), and (ii) to the ability
of melanoma cells to escape from natural, endogenous, or
therapeutically induced immune attacks (Gajewski, 2007).
Hypoxia favors melanoma progression (Bedogni and Powell,
2009), and melanomas are associated with marked neoangio-
genesis processes. Therefore, great hopes have been placed in
anti-angiogenic therapies to combat advanced melanomas
(Mansfield and Markovic, 2009; Marneros, 2009).
Galectin-1 (gal-1) belongs to a family of 15 b-galactoside-
binding proteins in mammals sharing a consensus carbohy-
drate recognition domain of 135 amino acids (Barondes
et al., 1994; Camby et al., 2006). Gal-1 and gal-3 are
hypoxia-regulated proteins (Greijer et al., 2005; Le et al.,
2005) that exert important roles in neoangiogenesis processes
(Thijssen et al., 2006, 2008, 2010).
Gal-1, -3, and -9 have been shown to participate in the
regulation of the tumor immune response (Rubinstein et al.,
2004; Liu and Rabinovich, 2010), adhesion, migration, and
metastasis (Danguy et al., 2002; Camby et al., 2006; Elola
et al., 2007); gal-1 and -3 participate in transformation and
proliferation (Paz et al., 2001; Elad-Sfadia et al., 2002, 2004),
apoptosis, and chemoresistance (Fukumori et al., 2007; Le
Mercier et al., 2008a); and gal-1 participates in stem cell
differentiation (Nasrabadi et al., 2010).
In melanoma cells, the expression of gal-1 and -3 in vitro
was first reported in 1989 (Lotan et al., 1989). Although data
regarding the potential roles of gal-1 in melanomas are much
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more limited than for gal-3 to date, we were nevertheless the
first to suggest a gal-1-mediated modulation of melanoma
cell adhesion to laminin (van den Bruˆle et al., 1995). Gal-1
and -3 are both associated with metastatic development in
experimental melanomas metastazing to the lungs (Rye et al.,
1998). In vivo administration of carbohydrate recognition
domain competitors decreases lung colonization by melano-
ma cells (Platt et Raz, 1992; Krishnan et al., 2005).
Considering the multifaceted roles of gal-1 reported above
with respect to cancer cell, as well as endothelial cell
biology, this study aims (i) to compare its expression level
with other galectins in benign nevi and melanoma progres-
sion and (ii) to further decipher mechanistically its differential
roles in cancer versus endothelial cell biology in the specific
lung context.
RESULTS
Gal-1 is more highly expressed than gal-3 and -9 in melanomas
Figure 1a–c illustrate the mRNA expression levels of gal-1, -3,
and -9, respectively, in a public Affymetrix data set relating to
samples from human normal skin (n¼7), benign nevi
(n¼18), and melanomas (n¼45). Although gal-9 mRNA
expression remains low in the three groups, gal-1 and -3
mRNAs are significantly higher in melanoma samples as
compared with normal or benign tissues. The mRNA
expression levels of the remaining galectins, i.e., gal-2, -4,
-7, -8, -13, and -14 were found in low amounts in all groups
except for gal-7 in the benign nevi group (data not shown).
The cellular effects of galectins can markedly vary in
function of their localizations (Califice et al., 2004). We thus
investigated gal-1,-3, and -9 cytoplasmic versus nuclear
protein expression by immunohistochemistry in a clinical
series of 57 benign nevi and 82 melanomas. Quantification of
the cytoplasmic versus nuclear (Table 1) gal staining
according to the Breslow index shows that (i) gal-1 is the
highest expressed gal as compared with gal-3 and gal-9 in
both cellular compartments, (ii) gal-1 is more highly
expressed in the cytoplasm of advanced melanoma lesions
as compared with gal-3 and -9, and (iii) gal-9 is poorly
expressed in all lesions as illustrated by examples in Figure
1f–n. Staining intensity was higher for gal-1 than for gal-3 in
advanced melanoma lesions (b3, b4, and MM) while being
very low for gal-9 (Table 1).
Gal-1 depletion extends survival of melanoma-bearing mice
To further examine a possible role of gal-1 in the metastatic
progression of melanoma, we evaluated the impact of its
downregulation in the B16F10 mouse melanoma model.
Among the 30 stable gal-1 knockdown (KD) B16F10 clones
that were engineered in the current study, the highest
decrease (B80%) in gal-1 expression was obtained in clone
1.3 (Figure 2a), which was selected for all subsequent studies
and further named KD.
Gal-1 KD versus mock and wild-type B16F10 cells were
grafted intravenously (tail vein) in immunocompetent mice.
Wild-type B16F10 melanoma cells formed aggressive lung
Figure 1. Galectin (gal)-1, -3, and -9 expression levels in tumor progression. The mRNA expression levels of (a) gal-1, (b) gal-3, and (c) gal-9 in the public
Affymetrix array data set GSE3189 (new genes associated with malignant melanoma but not benign melanocytic lesions) of normal skin samples (NS; n¼ 7),
benign nevi (BN; n¼ 18), and malignant melanomas (MM; n¼45). Data are expressed as mean±SEM and *** relates to P-value o0.001. (d) Typical
cytoplasmic and (e) nuclear strong staining (þ þ /þ þ þ ; GX400). Typical staining patterns of (f ) gal-1, (g) gal-3, and (h) gal-9 in a human benign composed
nevus, (i–k) the ones of a Dubreuil melanoma sample of Breslow index 4 (44mm; GX400) and (l–n) the ones of a brain metastatic melanoma lesion. Gal
immunostaining appears red, and slides have been counter-colored with hematoxylin–eosin. a.u., arbitrary units. Bar¼50 mm.
Table 1. Clinical data of galectins’ staining
Nevi B1 B2 B3 B4 MM
N 57 18 8 8 10 38
Cytoplasmic
Gal-1 ++/+++ (%) 93 82* 86* 57* 70 82
AREA (%) 61 62* 67* 73* 70 50
Gal-3 ++/+++ (%) 98* 81** 86* 88 80 84
AREA (%) 53* 50** 63* 34 33 32
Gal-9 ++/+++ (%) 35*** 33 78 86* 70 61
AREA (%) 31*** 17 23 21* 22 18
Nuclear
Gal-1 ++/+++ (%) 72 65* 71* 43* 100 Weak 61
AREA (%) 50 53* 66* 49* 79 40
Gal-3 ++/+++ (%) 48* 31** 72* 50 100 Weak 63
AREA (%) 37* 36** 44* 36 43 24
Gal-9 ++/+++ (%) 44*** 33 88 86* 70 63
AREA (%) 21*** 15 22 21* 16 15
Global
Gal-1 ++/+++ (%) 91 82* 86* 57* 70 79
AREA (%) 72 64* 67* 73* 70 63
Gal-3 ++/+++ (%) 88 56** 71* 63 20* 51*
AREA (%) 71 66** 69* 69 67* 60*
Gal-9 ++/+++ (%) 39*** 28 88 71* 50 55
AREA (%) 31*** 17 28 31* 29 21
Abbreviation: gal, galectin.
Each star (*) indicates that one clinical slide was missing within the group
regarding the gal studied. Only the percentage of strong intensities (++/
+++) is mentioned with the exception of the nuclear gal-1 and gal-3
staining in group B3, for which the staining intensity was weak in all cases
but in a large proportion of cells.
The groups B1–B4 relate to primary melanomas with Breslow index
categories 1–4; 1: Breslow o1mm; 2: Breslow between 1 and 2mm; 3:
Breslow between 2 and 4mm; 4: Breslow 44mm. MM relates to
metastatic melanomas.
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Figure 2. Galectin (gal)-1-deficient mouse melanoma models display increased survival. (a) Western blot analysis of gal-1 expression levels in wild-type
(WT), mock-transfected, and monoclonal (clone 1.3) gal-1 knockdown (KD) B16F10 melanoma cell lines; 20 mg of protein was loaded for each
sample. Integrity of the samples was assessed by tubulin immunoblotting. (b) This picture illustrates the macroscopic tumor that developed in the lungs of
immunocompetent mice that were grafted in the tail vein with murine B16F10 melanoma cells. Hematoxylin–eosin (HE) staining pictures at (c) GX100 and
(d) GX400 of the tumor that developed in the lung parenchyma. Bar¼ 100mm. (e) This graph presents the Kaplan–Meier survival curves of mice (eight mice
per experimental group) grafted with wild-type versus gal-1-deficient melanoma cells into their tail veins (black squares: wild-type group; open dots: mock
transfected group; black triangles: clone 1.3). (f) A similar survival curve was drawn when the same cell subtypes were grafted in gal-1 knockout (KO)
mice. Same legend. Videomicroscopic pictures after 72 hours of observation of (g) wild-type and (h) gal-1-KD B16F10 melanoma cells. Bar¼100 mm.
(i) Quantification of the number of cells over time shows that gal-1 depletion markedly reduces cell proliferation.
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Figure 3. Galectin-1-deficient endothelial cell properties. (a) Isolation of primary lung mouse endothelial cells (LMEC) with (aA) Dynabeads and (aB)
typical endothelial morphology obtained after the second marker selection (passage 1). (b) Immunofluorescence staining of WTLMECs for PECAM-1 and
ICAM-2 after the primary isolation with anti-PECAM-1 antibody. Arrows on the merged pictures point to the rare unstained cells (o5% of the whole population)
before the second sorting. Similar results were obtained for KOLMEC (data not shown). (c, d) The ability of the LMEC to form a tubular network when cultured on
Matrigel: whereas (c) WTLMECs form such networks 3 hours after the seeding, (d) KOLMECs cannot. Observation was continued for 48 hours without
any success. (e) WTLMECs became senescent after three passages with the active beta-galactosidase stained in blue. Quantification of the percentage of
beta-galactosidase-positive cells over the passages is presented in f. Data are presented as mean±SEM of 10 fields per flask; IxPy: x and y relate to the isolation
assay and cell culture passage numbers, respectively. Bar¼ 100mm.
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tumors (pseudometastases) as observed 3 weeks after their
injection (Figure 2b–d).
Survival analysis shows that gal-1-competent mice grafted
with gal-1 KD B16F10 cells survived significantly longer than
the control groups (P¼0.015; Figure 2e). Similar results were
obtained when the B16F10 melanoma cell subtypes (wild
type, mock, and KD) were grafted in gal-1-deficient (knock-
out) mice (Figure 2f). The lack of differences between data
obtained in gal-1-competent (Figure 2e) versus gal-1 knock-
out mice (Figure 2f) suggest that the aggressiveness of the
intravenous B16F10 melanoma model relates mainly to the
B16F10 cell-related content in gal-1 and not to the host
(mice) content in gal-1. We recently showed that gal-1-
deficient endothelial cells can take up the tumor-secreted
gal-1 for angiogenesis (Thijssen et al., 2010). As gal-mediated
interactions between cancer cells and microvessel endothe-
lial cells have important roles in melanoma metastases and
progression (Platt et Raz, 1992; Rye et al., 1998; Krishnan
et al., 2005), we further investigated gal-1-mediated effects
and signaling pathways not only in B16F10 melanoma cells
but also in primary lung endothelial cells as detailed below.
Gal-1 depletion modifies the growth properties of melanoma
cells in vitro
Although control B16F10 cells rapidly reached confluency
after subculture, gal-1 depletion markedly decreased the
global growth rate of B16F10 cells (Figure 2g–i).
Gal-1 depletion impairs angiogenic properties of endothelial
cells but rescues primary endothelial cells from early cell cycle
arrest
As illustrated above, B16F10 melanoma cells home in the
lungs after intravenous injection and thus need to interact
with lung microvessel endothelial cells (LMECs). To study the
possible influence of gal-1 on the vascular compartment of
metastases, we isolated LMECs from wild-type (WTLMECs)
versus gal-1 knockout mice (KOLMECs) by two consecutive
sortings with magnetic Dynabeads coated with PECAM-1 and
ICAM-2 LMEC cell markers, respectively (Figure 3aA).
Isolated LMECs exhibited typical endothelial cell morphology
(Figure 3aB); purity of the cell populations was assessed by
immunofluorescence for both PECAM-1 and ICAM-2 markers
as illustrated in Figure 3bA and bB.
When cultured on Matrigel, the WTLMECs form tubular
networks (Figure 3c) to a larger extent than KOLMECs (Figure
3d), which is in accordance with previous published results
that demonstrated the roles of gal-1 in neoangiogenesis
(Thijssen et al., 2006, 2008, 2010).
Among five independent WTLMEC cell isolation assays,
only three succeeded in obtaining growing cell culture until
passages three to four, whereas the two unsuccessful assays
could not reach passage one. By contrast, KOLMEC cells
were proliferating until at least passage nine in two of the
four experimental isolations performed. Determination of
b-galactosidase activity revealed that at least 25% of WTLMECs
were senescent at passage three (Figure 3e and f), whereas the
proportion of senescent cells in KOLMECs remained o10%
over the passages (at least until passage nine; Figure 3f).
Gal-1-related effects on cell growth depend on the p53/p21
pathway that can be triggered by Ras
Senescence in normal cells such as fibroblasts was shown
previously to depend on Ras signaling. Ras can actually trigger
proliferation signals in malignant cells and senescence in
primary fibroblast cell cultures (Benanti and Galloway, 2004).
Considering the fact that gal-1 has a critical role in the plasma
membrane anchorage of H-Ras and its subsequent signaling
(Paz et al., 2001; Elad-Sfadia et al., 2002; Belanis et al., 2008),
we hypothesized that gal-1 depletion could lead to opposite
consequences in B16F10 melanoma cells and ‘‘healthy’’
LMECs. Indeed, although gal-1 KD induces a marked increase
in p53 expression level in melanoma cells, (Figure 4a) as
previously reported in the case of glioma cells (Camby et al.,
2005), KOLMECs display a lower level of this protein as
compared with WTLMECs (Figure 4b). This observation was
confirmed by immunofluorescence: although p53 and its
downstream target p21 are overexpressed in gal-1 KD B16F10
melanoma cells (Figure 4c), their expression levels are
markedly decreased in KOLMECs as compared with
WTLMECs (Figure 4d). Other important controllers of the cell
cycle and the induction of senescence, i.e., p16 and Rb, have
also been investigated but were not expressed at detectable
levels in our samples (Figure 4a and b). Although the total
level of Ras does not seem to be altered by gal-1 depletion
(Figure 4a and b), its expression pattern and distribution
could be modified when comparing gal-1-expressing versus
gal-1-depleted cells as presently revealed by optical sections
in the case of LMECs: plasma membrane–associated Ras
appears more marked in KOLMECs than in the WTLMECs
(Figure 4d).
DISCUSSION
Gal-1 is expressed in a large set of human tumor types
(Danguy et al., 2002; Liu and Rabinovich, 2005; Demydenko
and Berest, 2009). Although major attention has been paid
to gal-3 and -9 in melanomas, the current study indicates
that gal-1 is more highly expressed in advanced melanoma
lesions than the other galectins. We accordingly show here
that stable gal-1 depletion in B16F10 melanoma cells reduces
their proliferation rate in vitro and thereby partly increases
the survival of mice grafted with those cells (vs. wild-type
B16F10 cell administration). Our data further revealed that
gal-1 depletion in host mice (i.e., gal-1 KO mice) did not
contribute higher benefits in terms of survival, indicating that
the melanoma cell contribution to the gal-1 pool of the lung
metastases is more critical than that of the host. In addition to
the capacity of endothelial cells to take up the tumor-secreted
gal-1 to stimulate neoangiogenesis (Thijssen et al., 2010),
compensatory mechanisms may have been activated in
knockout mice but not in vitro in melanoma cells. Never-
theless, a similar phenomenon was also observed in the case
of gal-3 KO mice (Thijssen et al., 2008; Eude-Le Parco et al.,
2009). Interestingly, besides the confirmation of the pro-
angiogenic role of gal-1, our data identified a role of gal-1 in
the regulation of cell senescence. In particular, we docu-
mented the gal-1-dependent senescence of the cells located
at the interface between circulating B16F10 melanoma cells
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and the host lung tissues, namely the lung microvascular
endothelial cells.
The present study shows that gal-1 depletion decreases the
proliferation of melanoma cells, whereas it rescues primary
lung mouse endothelial cells from early cell cycle arrest. To
understand the opposite roles of gal-1 on melanoma and lung
microvascular endothelial cells, we examined the influence
of gal-1 downregulation on the expression of Ras and p53,
two key regulators of cell survival and senescence, further
noting that gal-1 was previously reported to be a key partner
of Ras: gal-1 is required to anchor the active farnesylated
form of Ras at the plasma membrane (Paz et al., 2001;
Belanis et al., 2008) and leads to the stimulation of cancer
cell proliferation and survival (Schubbert et al., 2007). The
decrease in melanoma cell proliferation observed in gal-1 KD
B16F10 cells could result from the impairment of Ras activity.
In gal-1 KD B16F10 cells, we also identified a marked
increase of both p53 and p21 expression levels (vs. wild-type
B16F10 cells). These data support a decreased apoptotic
potential of gal-1-expressing tumor cells; such link between
gal-1 expression and p53 induction was already observed in
glioma cells (Camby et al., 2005). In contrast, lack of gal-1 in
LMECs was associated with a reduced expression of p53 and
p21, which was in accordance with a reduced or delayed
senescence. Normal cells have been shown to either senesce
or transform in response to H-Ras-induced expression in a
cellular status– and context-dependent manner (Benanti and
Galloway, 2004). Ras family members’ oncogenic roles in
cancer cell proliferation and survival are largely documented
(Schubbert et al., 2007). However, transduced expression of
H-Ras in normal fibroblasts or keratinocytes can induce their
senescence (Serrano et al., 1997; Lin and Lowe, 2001). Two
major pathways have been identified in this process: p16/Rb
and p53/p21 through or not through Rb, although their
respective roles remain controversial (Serrano et al., 1997;
Benanti and Galloway, 2004; Yaswen and Campisi, 2007). In
fact, the requirements for maintaining senescence arrest are
less well known than the requirements to establish it.
Replicative senescence can be reversed by p53 inactivation,
but only in p16-negative cells (Beause´jour et al., 2003).
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Figure 4. Identification of the molecular pathways involved in galectin (gal)-1-dependent modifications of the growth properties of melanoma cells
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Therefore, p16 seems to be a dominant irreversible barrier to
cell proliferation (Beause´jour et al., 2003). Here we show that
gal-1 KOLMEC cells exhibit decreased expression levels of
both p53 and p21, both WTLMEC and KOLMEC cells being
p16 and Rb negative. These results therefore completely fit
with the senescence reversal pathway published previously in
the case of fibroblasts (Beause´jour et al., 2003). Moreover,
endothelial cell senescence has been later related to
inhibition of the CDK2 activity that results from both a
reduced CDK2 expression level and CDK2 inhibition by p21
but is independent of p16 (Freedman and Folkman, 2005).
Finally, p53- but not p16-dependent cell senescence has
been linked to the production of reactive oxygen species
(ROS), notably in the context of normal endothelial cells (Cho
et al., 2011), whereas tumor aggressiveness and neoangio-
genesis can be both increased by Akt and/or NOX-1-induced
ROS (Arbiser et al., 2002; Govindarajan et al., 2007).
Therefore, ROS could be key mediators of the gal-1 opposite
cell cycle regulation in cancer versus endothelial cells observed
in the present study, especially when considering that galectins’
expression or signaling has been associated with ROS pro-
duction (Mendelsohn et al., 2007; Zhuravliova et al., 2009).
Our study therefore emphasizes gal-1 as a key target to
combat cancer progression, by acting not only on tumor cells
but also on host endothelial cells. First, our data confirm the
anti-angiogenic potential of blocking gal-1 effects as pre-
viously demonstrated with the anginex anti-angiogenic
peptide whose activity depends on direct gal-1 binding
(Thijssen et al., 2006). Second, our study provides evidence
for a direct link between gal-1 and the senescence of lung
microvascular endothelial cells. Blocking the effects of gal-1
may reduce the homing of circulating tumor cells and thereby
decrease metastatic spreading. Interestingly, salirasib, a
compound in phase II clinical trial evaluation designed to
inhibit H-Ras signaling was shown to compete for the gal-1
binding site with farnesylated H-Ras (Paz et al., 2001).
Considering the fact that salirasib preferentially inhibits the
plasma membrane anchorage of the active H-Ras 12V form in
comparison with the wild-type form, such compounds could
differentially act on the oncogenic versus senescent H-Ras
pathways. In addition to anginex and salirasib, the silencing
of gal-1 using dedicated siRNA could also be used to combat
melanomas. We already demonstrated in vivo the feasibility
of such an approach not only in experimental melanomas
(Mathieu et al., 2007) but also in experimental gliomas (Le
Mercier et al., 2008b).
In conclusion, our study has documented that the highly
expressed gal-1 in aggressive melanoma actively participates
in the metastatic progression of the disease. Besides the
already well-documented pro-angiogenic and trophic effects
of gal-1, our study unravels a role of gal-1 in the senescence
of lung microvascular endothelial cells at the metastatic site.
This process is supported by a distinct capacity of melanoma
cells and host endothelial cells to stimulate the p53/p21
pathway that could depend on Ras. More generally, this study
gives more credential to strategies such as anginex, salirasib,
and anti-gal-1 siRNA, aiming to interfere with gal-1 functions
in cancers and, in particular, in melanoma.
MATERIALS AND METHODS
Antibodies
All antibodies used in the present study are detailed in the
Supplementary Information online.
Cell cultures
B16F10 mouse melanoma cells (ATCC code CRL-6475) were
purchased from the ATTC (Manassas, VA) and cultured as previously
described (Mathieu et al., 2007).
Construction of gal-1-depleted B16F10 mouse melanoma cells
Stable KD cells were generated using HIV-based vectors encoding
the miRNA-based short-hairpin RNAs against gal-1 with a blasticidin
resistance cassette; 30 monoclonal gal-1 KD cell lines were
generated. Selection of the best clones was based on their gal-1
expression level as determined by western blot analysis. The detailed
procedure is described in the SI section.
Quantitative videomicroscopy
Computer-assisted phase contrast microscopy (quantitative video-
microscopy) enabled us to follow and quantify the growth rates and
behavior of B16F10 melanoma cell subtypes over a 72-hour period,
as detailed in Debeir et al. (2008).
Primary endothelial cell isolation and culture
Lung mouse endothelial cells (LMECs) were isolated as described by
Lim et al. (2003). Briefly, lungs from three mice were collected,
minced, and digested in collagenase IV (Worthington, Gestimed,
Brussels, Belgium) for 1hour at 37 1C under agitation. After filtration
(40mm BD filter), cells were centrifuged and incubated with
Dynabeads coated with anti-PECAM-1 antibody (BD Pharmingen,
Erembodegem, Belgium) at room temperature for 30–60 minutes under
agitation. After magnetic separation and three washing steps, cells were
allowed to adhere and grow in a 25-cm2 flask coated with fibronectin
(2.5mgcm2, Millipore, Brussels, Belgium). When cells reached conflu-
ence, they were detached with trypsin-EDTA (Invitrogen, Merelbeek,
Belgium) for their first passage, centrifuged, and sorted again with
Dynabeads coated with anti-ICAM-2 antibody (BD Pharmingen) as
detailed above. The detailed procedure and product references are
available at http://vrd.bwh.harvard.edu/core_facilities/mlec.html.
Five (wild-type mice) and four (gal-1 KO C57Bl/6 mice) distinct
isolations have been performed (see in vivo experiments).
Tubulogenesis
For the tubulogenesis assay, 100,000 endothelial cells were seeded in
500-ml endothelial growth medium on pure Matrigel (BD Bio-
sciences, Erembodegem, Belgium) matrix in 24-well plates. Pictures
of the network formed were taken 3 hours after the seeding. We
followed this for 48 hours after the seeding to monitor for late
development. The experiment was conducted in triplicate.
Senescence assay
Senescent cells display increased beta-galactosidase levels (Itahana
et al., 2007). Therefore, beta-galactosidase activity measurement
was conducted with the colorimetric Senescence Detection Kit
(Sigma-Aldrich, Bornem, Belgium) following the manufacturer’s
recommendations. X-gal is an organic compound of galactose linked
to a substituted indole that is cleaved by b-galactosidase, yielding
galactose and 5-bromo-4-chloro-3-hydroxyindole. The latter is then
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oxidized into 5,50-dibromo-4,40-dichloro-indigo, an insoluble blue
product. The lung mouse endothelial cells were evaluated after each
passage 3–5 days following seeding in 12.5-cm2 flasks. Ten fields
(GX10) per flask were quantified for the proportion of beta-
galactosidase-positive cells.
Protein expression pattern evaluation
Western blot. Gal-1 expression level in the various monoclonal
melanoma cells was evaluated by means of western blot analysis as
previously described (Mathieu et al., 2007). The integrity and equal
loading of the extracts were evaluated by tubulin or GAPDH blot.
Quantification of the signal was determined using the Aida Software
and has been normalized against the background.
Immunofluorescence. For immunofluorescence staining, cells
were cultivated on glass coverslips for 48–72 hours and fixed with
3.5% formalin in phosphate-buffered saline for 20minutes at 4 1C.
Cells were permeabilized with 0.2% Triton X-100 for 10minutes at
room temperature when required. Antibodies and dilutions are
provided in the SI section. Images were collected with a Zeiss Axio
microscope (Zeiss, Zaventem, Belgium).
Fluorescence assays on LMECs have been performed on the fixed
materials for the beta-galactosidase staining. The fixative solution is a
mixture of formaldehyde and glutaraldehyde (Sigma-Aldrich, Senes-
cence Detection Kit). Therefore, the aldehyde groups that could lead
to nonspecific staining were reduced with NaBH4 in phosphate-
buffered saline (0.5mgml1), pH 8.0, for 10minutes and repeated
three times after a short permeabilization in 100% ice-cold methanol
(10 seconds) before the staining procedure described above.
Ras imaging microscopy was realized on plastic coverslips
fixed with a mixture of formaldehyde and glutaraldehyde (Sigma-
Aldrich, Senescence Detection Kit) and permeabilized with 0.2%
Triton  100 for 10minutes. Nonspecific reaction and/or binding
were avoided by incubation with 1% FBS in phosphate-buffered
saline for 30minutes before staining. Plasma membrane was
visualized by Alexa Fluor 488–coupled phalloidin (Molecular
Probes, Invitrogen). Optical sectioning was obtained by structured
illumination using an Apotome system (Zeiss) coupled to an
AxioImager microscope (Zeiss) and analyzed using the dedicated
AxioVision software (Zeiss).
Microarray data management
We analyzed the mRNA expression levels of galectins in the public
data set GSE3189 (GPL96 platform, GEO DataSets, PubMed
database). It was obtained with the Affymetrix Human Genome
U133A Array (Affymetrix, Santa Clara, CA). mRNA expression data
are presented in the database as normalized values in arbitrary units
and are therefore ready to use. All gal data were selected for further
analysis. Gal-2, -3, -4, -7, -9, -13, and -14 were represented on the
array by one oligo, gal-1 by two oligos, and gal-8 by six oligos. The
data set contains 7 normal skin samples, 18 benign nevi, and 45
melanomas. Expression level of gal varied from 5 to 55, 563 arbitrary
units. Comparison between the groups has been made both
separately on each oligo and on their mean in case of multiple
oligos. For gal-1, among the two oligos of the array, we present here
only the data for one of them, because the second one displayed
values around 100 arbitrary units. However, its significant increased
expression level in metastatic lesions was obtained with both oligos.
Immunohistological staining
Immunohistochemical expression of gal-1, -3, and -9 was determined
on a series of 139 clinical samples including 57 nevi and 82
melanomas (Table 1). Samples were obtained from the Poˆle de
Biologie, Pathologie et Ge´ne´tique (CHRU Lille Hospital, France), and
the Erasmus University Hospital (Brussels, Belgium). Four consecu-
tive 5-mm slides were used for each case for one hematoxylin–eosin
and the three gal stainings. The semiquantitative analysis was
performed by a specialized pathologist and assessed global,
cytoplasmic, and nuclear expressions (Figure 1d and e) in terms of
the percentage of cells stained and the intensity of staining (0/þ vs.
þ þ /þ þ þ , see Figure 1k and g or i respectively).
In vivo experiments
Five-hundred thousand mouse melanoma cells were injected
intravenously in the tail vein of the mice. Wild-type 6-week-old
C57BL/6 mice were purchased from Charles Rivers (Arbresle,
France). Knockout mice have been generated and bred in our lab
(Poirier and Robertson, 1993). Each group contained eight mice.
The in vivo experiment described in the present study was
conducted on the basis of Authorization No. LA1230568 of the
Animal Ethics Committee of the Federal Department of Health,
Nutritional Safety and the Environment (Belgium).
Statistical analysis
Statistical comparisons between groups were established by carrying
out the Kruskal–Wallis test. Survival analyses were carried out by
means of Kaplan–Meier curves and log-rank tests. All statistical
analyses were performed using Statistica (Statsoft, Tulsa, OK).
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